Abstract
VA21B7 (3-[2-(4′-piperonylpiperazinyl) indolyl] carboxaldehyde) was synthesized as a potential 5-HT3 receptor antagonist. Even though VA21B7 showed a higher affinity towards 5-HT3 receptors as compared to other receptors studied, it was not a potent 5-HT3 receptor antagonist either in the periphery or in the brain. In a simple animal model of anxiety such as the two-compartment box in mice, a remarkable anxiolytic-like effect was found at doses of 2–500 µg/kg IP and also at low oral doses, in the microgram range. These drug doses did not produce any significant effect on spontaneous motor activity of mice. The anxiolytic profile of VA21B7 was further explored using other models of anxiety in rats such as the elevated plus-maze and punished-drinking. VA21B7 was compared with standard 5-HT3 receptor antagonists such as ondansetron, tropisetron and granisetron, with the 5-HT1A agent buspirone and with diazepam. In the plus-maze, VA21B7 showed an anxiolytic-like profile after doses of 0.25–0.5 mg/kg IP or 2–4 mg/kg PO which did not modify the number of total entries into the open and closed arms of the maze. Diazepam, granisetron and tropisetron were also effective in this test but not ondansetron and buspirone. VA21B7 was also able to release suppressed behaviour in the punished-drinking test. The dose-response curve was bell-shaped with a peak at 2–4 mg/kg. At variance with other studies, 5-HT3 receptor antagonists also increased the number of shocks taken in this test and the dose-response curve was also bell-shaped. VA21B7 was not anticonvulsant like diazepam, its anxiolytic action in the light/dark test was not flumazenil-sensitive and there was no rebound anxiogenic effect on withdrawal from chronic VA21B7 treatment for 15 consecutive days. Moreover, VA21B7 was not amnesic like the benzodiazepines but low doses of 2–4 mg/kg reduced the memory deficits induced in rats by scopolamine. Much higher doses were necessary to decrease spontaneous motor activity in rats. Since VA21B7 appears to be well tolerated in rodents at high doses, we think that it is of potential interest as an anxiolytic in humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alhaider AA (1991) Antinociceptive effects of ketanserin in mice: involvement of supraspinal 5-HT2 receptors in nociceptive transmission. Brain Res 543:335–340
Andrews N, File SE (1993) Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology 112:21–25
Barnes JM, Barnes NM, Costall B, Naylor RJ, Tyers MB (1989) 5-HT3 receptors mediate inhibition of aceylcholine release in cortical tissue. Nature 338:762–763
Barnes JM, Barnes NM, Cooper SJ (1992a) Behavioural pharmacology of 5-HT3 receptor ligands. Neurosci Biobehav Rev 16:107–113
Barnes NM, Cheng CHK, Costall B, Ge J, Kelly ME, Naylor RJ (1992b) Profiles of interaction ofR(+)/S(−) zacopride and anxiolytic agents in a mouse model. Eur J Pharmacol 218:91–100
Barnes NM, Cheng CHK, Costall B, Ge J, Naylor RJ (1992c) Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex byR(+) andS(−) zacopride. Br J Pharmacol 107:233–239
Barret JE, Vanover KE (1993) 5-HT receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 112:1–12
Baxter GS, Craig DA, Clarke D (1991) 5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae. Naunyn-Schmiedeberg's Arch Pharmacol 343:439–446
Bonhaus DW, Wong EHF, Stefanich E, Kunysz EA, Eglen RM (1993) Pharmacological characterization of 5-hydroxytryptamine3 receptors in murine brain and ileum using the novel radioligand [3H] RS-42358-197: evidence for receptor heterogeneity. J Neurochem 61:1927–1932
Buchheit KH, Engel G, Mutschlen E, Richardson B (1985) Study of the contractile effect of 5-HT in the isolated longitudinal muscle strip from guinea-pig ileum. Naunyn-Schmiedeberg's Arch Pharmacol 329:36–41
Cheng Y, Prussoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Chugh Y, Saha N, Sankaranayanan A, Sharma PL (1991) Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur J Pharmacol 203:121–123
Cohen ML, Fuller RW, Wiley KS (1981) Evidence for 5-HT2 receptors mediating contraction in vascular smooth muscle. J. Pharmacol Exp Ther 218:421–425
Corradetti R, Ballerini L, Pugliese AM, Pepeu G (1992) Serotonin blocks the long-term potentiation induced by primed burst stimulation in the CA1 region of rat hippocampal slices. Neuroscience 46:511–518
Costall B, Naylor RJ (1991) Anxiolytic effects of 5-HT3 antagonists in animals. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. Wiley, Chichester, pp 133–157
Costall B, Naylor RJ (1993) The pharmacology of the 5-HT4 receptors. Int Clin Psychopharmacol 8 [S2]:11–18
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR-38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894
Costall B, Jones BJ, Kelly ME, Naylor RJ, Oakley NR, Onaivi ES, Tyers MB (1989) The effects of ondansetron (GR 38032F) in rats and mice treated subchronically with diazepam. Pharmacol Biochem Behav 34:769–778
Costall B, Jones BJ, Kelly ME, Naylor RJ, Onaivi ES, Tyers MB (1990a) Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Behav 36:339–344
Costall B, Naylor RJ, Tyers MB (1990b) The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 47:181–202
Crawley JN, Goodwin FK (1980) Preliminary report of a simple animal behaviour model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167–170
Dauge V, Bohme GA, Crawley JN, Durieux C, Stutzmann JM, Feger J, Blanchard JC, Roques BB (1990) Investigation of behavioural and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog: BC 264. Synapse 6:73–80
Del Río J, Artaiz I, Zazpe A, Romero G, Monge A, Roca J, Lasheras B (1993) VA21B7: an atypical 5-hydroxytryptaminergic anxiolytic. Br J Pharmacol 110 [suppl]: 11P
De Veaugh-Geiss J, McBain S, Cooksey P, Bell JM (1992) The effects of a novel 5-HT3 antagonist, ondansetron, in schizophrenia. Results from uncontrolled trials. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven, New York, pp 225–232
Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Balscko H, Muscholl E (eds) Handbook of experimental pharmacology. Springer, Berlin, pp. 283–335.
Handley SL, Mc Blane JW (1993) 5-HT drugs in animal models of anxiety. Psychopharmacology 112:13–20
Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding sites with [3H]5-HT, [3H]8-OH-DPAT, [125I]-iodocyanopindolol, [3H]mesulergine and [3H]-ketanserin. Eur J Pharmacol 118:13–23
Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233–236
Irwin S (1968) Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacologia 3:222–257
Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR 38032F, a novel 5-HT3-receptor antagonist. Br J Pharmacol 93:985–993
Katz Y, Amiri Z, Weizman A, Gavish M (1990) Identification and distribution of peripheral benzodiazepine binding sites in male rat genital tract. Biochem Pharmacol 40:817–820
Kidd E, Bouchelet de Vendegies I, Levy JC, Hamon M, Golzan H (1992) The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system. Eur J Pharmacol 211:133–136
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in the rat brain using radioligand binding. Nature 330:746–748
Lecrubier Y, Puech AJ, Azcona A, Bailey PE, Lataste X (1993) A randomized double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 112:129–133
Leysen JE, Goumeren W, Laduron PM (1978) Spiperone: a ligand of choice for neuroleptic receptor 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 27:307–316
Leysen JE, Niemegeers CJE, Van Nauten JM, Laduron PM (1982) [3H] Ketanserin (R41468) a selective [3H]-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:301–314
Matsuoka N, Maeda N, Yamazaki M, Ohkubo Y, Yamaguchi I (1992) Effect of FR 121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks. J Pharmacol Exp Ther 263:436–444
Meneses A, Hong E (1993) Modification of the anxiolytic effects of 5-HT1A agonists by shock intensity. Pharmacol Biochem Behav 46:569–573
Möhler H, Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849–851
Moser PC (1989) An evaluation of the elevated-plus maze test using the novel anxiolytic buspirone. Psychopharmacology 99:48–53
Nelson DR, Thomas DR (1989)3H-BRL 43694 (granisetron), a specific ligand for 5-HT3 binding sites in rat brain cortical membranes. Biochem Pharmacol 38:1693–1695
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 14:149–167
Peroutka SJ, Lebovitz RM, Synder SH (1979) Serotonin receptor binding sites affected differentially by guanine nucleotides. Mol Pharmacol 16:700–708
Richardson BP, Engel G (1986) The pharmacology and function of 5-HT3 receptors. Trends Neurosci 9:424–428
Sanger GJ, Nelson DR (1989) Selective and functional 5-hydroxytryptamine-3 receptor antagonism by BRL 43694 (Granisetron). Eur J Pharmacol 159:113–124
Stefanski R, Palejko W, Bidzinski A, Kostowski W, Plaznik A (1993) Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like actions of the 5-HT3 receptor antagonists. Neuropharmacology 32:987–993
Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1–7
Weisberg E, Teitler M (1992) Novel high-affinity3H-serotonin binding sites in rat and bovine brain tissue. Drug Dev Res 26:225–234
Wong EHF, Bonhaus DW, Lee JA, Wu I, Loury DN, Eglen RM (1993a) Different densities of 5-HT3 receptors are labeled by [3H] quipazine, [3H] GR-65630 and [3H] granisetron. Neuropharmacology 32:869–875
Wong EHF, Bonhaus DW, Wu I, Stefanich E, Eglen RM (1993b) Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197. J Neurochem 60:921–930
Yaksh TL, Rudy T (1976) Chronic catheterization of the spinal subarachnoid space. Physiol Behav 17:1031–1036
Young R, Johnson DN (1991) Anxiolytic-like activity ofR(+) andS(−) zacopride in mice. Eur J Pharmacol 201:151–155
Zifa E, Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401–458
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Artaiz, I., Romero, G., Zazpe, A. et al. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology 117, 137–148 (1995). https://doi.org/10.1007/BF02245179
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02245179